Towards an optimum strategy in rheumatoid arthritis

The Lancet

Volumn 379, Issue 9827, 2012, Pages 1682-1684

  Emery, Paul ^a,b   Buch, Maya H ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; MONOTHERAPY; NOTE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIODIAGNOSIS; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

EID: 84860533319     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60164-0     Document Type: Note

References (13)

1. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission. Ann Rheum Dis 1995;54:944-47.
2. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-37.
3. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74.
4. St Clair EW, van de Heijde D, Smolen JS, et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group: combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum 2004;50:3432-43.
5. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
6. van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009;374:459-66.
7. van Vollenhoven RF, Geborek P, Forslind K, et al, for the Swefot study group. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis:2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012; published online March 29. DOI:10.1016/S0140-6736 (12) 60027-0.
8. Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford) 2007;46:1153-56.
9. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012;156:329-39.
10. Emery P, Kvien TK, Combe B, et al. Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis 2012; published online March 8. DOI:10.1136/annrheumdis-2011-201066.
11. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
12. Emery P, Smolen JS, Kavanaugh A, et al. Maintenance of biologic-free disease control in early rheumatoid arthritis patient after induction of low disease activity with adalimumab plus methotrexate. Ann Rheum Dis 2011;70(suppl 3):262-63.
13. Saleem B, Brown AK, Keen H, et al. Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. Ann Rheum Dis 2011;70:792-98.